Preparation containing cetirizine and herba artemisiae scopariae extract for treating rhinitis and preparation method thereof

Abstract

The invention belongs to the technical field of anti-allergic medicines, and particularly relates to a preparation containing cetirizine and a herba artemisiae scopariae extract for treating rhinitis and a preparation method of the preparation. The preparation containing cetirizine and the herba artemisiae scopariae extract is prepared from cetirizine hydrochloride, the herba artemisiae scopariae extract, a disintegrating agent, a lubricating agent and a filling agent, the extraction method of the herba artemisiae scopariae extract is improved, and the extraction efficiency of effective components is improved; it is verified that combined medication of cetirizine hydrochloride and the herba artemisiae scopariae extract can improve the treatment effect on allergic rhinitis.

Description

Technical Field

[0001] The invention belongs to the technical field of antiallergic drugs, and particularly relates to a preparation containing cetirizine and capillaris extract for treating rhinitis and a preparation method thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] The chemical formula of cetirizine hydrochloride is C 21 H 27 Cl3N2O3 is the metabolite of hydroxyzine in the human body. Animal experiments have shown that cetirizine hydrochloride is a peripheral H1 receptor antagonist that can inhibit the transmission and action of histamine, as well as vasoactive peptides and substance P involved in allergic reactions, reduce the movement of inflammatory cells, effectively inhibit skin allergic reactions, and significantly reduce the tracheal allergic reactions caused by histamine in asthma patients, and reduce allergic reactions caused by specific allergens. It is commonly used clinically to treat seasonal and perennial allergic rhinitis, rhinocorticitis, urticaria, and allergic reactions caused by drugs, food, and insect bites.

[0004] Artemisia capillaris is a traditional Chinese medicine, mainly used to clear away heat and detoxify, and to relieve dampness and jaundice. Artemisia capillaris extract is often used in pharmaceuticals and contains a variety of bioactive ingredients, such as chlorogenic acid, volatile oils, ketones, etc., which have anti-inflammatory and antioxidant effects.

[0005] So far, it has not been found that Artemisia capillaris and its extracts can be used as anti-allergic drugs. Summary of the invention

[0006] The invention provides a preparation containing cetirizine and Artemisia capillaris extract, a preparation method and use of the preparation in preparing a medicine for treating rhinitis.

[0007] The preparation containing cetirizine and Artemisia capillaris extract consists of the following components:

[0008]

[0009]

[0010] Among them, the disintegrant is selected from one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone; the lubricant is selected from one or more of magnesium stearate, talc, and micro-powdered silica gel; the filler is selected from one or more of microcrystalline cellulose, lactose, mannitol, sucrose, starch, and dextrin.

[0011] Furthermore, the preparation method of the Artemisia capillaris extract is:

[0012] (1) Take Artemisia capillaris, soak it in 85% to 90% ethanol as a solvent for 20 to 30 hours, then perform percolation, collect the percolation liquid, filter, and decompress the filtrate to a clear paste with a relative density of 1.10 to 1.15, add 6 to 8 times the amount of water, refrigerate, let stand, filter, heat the filtrate at 100° C. to 120° C. for 1 to 2 hours, refrigerate at 2° C. to 8° C., let stand, add 0.1% to 0.5% activated carbon, and filter to obtain filtrate A;

[0013] (2) After washing the residue, add 0.01 to 0.05 times the amount of sodium bicarbonate and 3 to 5 times the amount of water for distillation, and collect the distillate;

[0014] (3) The distillate is mixed with the filtrate A, concentrated under reduced pressure to a clear paste with a relative density of 1.15 to 1.20, and dried under vacuum at 65°C to 80°C to obtain the product.

[0015] The preparation method of the preparation containing cetirizine and Artemisia capillaris extract comprises the following steps:

[0016] Cetirizine hydrochloride is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granules A; an Artemisia capillaris extract is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granules B; granules A and B are mixed, a disintegrant and a lubricant are added, and the mixture is uniformly mixed to prepare a preparation.

[0017] Specifically, the preparation is a tablet, granule or capsule.

[0018] The present invention also verifies the application of the preparation containing cetirizine and Artemisia capillaris extract in the preparation of medicine for treating rhinitis.

[0019] Compared with the prior art, the technical effects of the present invention are:

[0020] The study found that the combined use of cetirizine hydrochloride and Artemisia capillaris extract can improve the therapeutic effect of allergic rhinitis. Cetirizine hydrochloride and Artemisia capillaris extract are rationally combined and prepared into a pharmaceutically acceptable dosage form together with excipients for easy medication. In addition, the extraction method of Artemisia capillaris extract was improved in combination with the method in the Chinese Pharmacopoeia, which improved the extraction efficiency of the effective ingredients and helped cetirizine hydrochloride to exert a better anti-allergic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 : Effect of sodium bicarbonate on the extraction efficiency of volatile oil.

[0022] Figure 2 : The number of sneezing of rats in each group during the drug administration period.

[0023] Figure 3 : The number of times the rats in each group wiped their noses during the drug administration period.

[0024] Figure 4 : Expression of serum IgE levels in rats of each group.

[0025] Figure 5 : EOS levels in nasal secretions of rats in each group after administration. DETAILED DESCRIPTION

[0026] In order to make the purpose and technical solution of the present invention clearer, the present invention is further described below in conjunction with embodiments, but the protection scope of the present invention is not limited to these embodiments, and the embodiments are only used to explain the present invention. It should be understood by those skilled in the art that any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.

[0027] 1. Preparation of Artemisia capillaris extract

[0028] Example 1 Preparation of Artemisia capillaris extract

[0029] (1) Remove impurities from the Artemisia capillaris, wash, chop, and dry in the sun. Take 50 g of the treated Artemisia capillaris, soak it in 90% ethanol as a solvent for 24 hours, and then perform percolation. Collect the percolation liquid, filter, and decompress the filtrate to a clear paste with a relative density of 1.10 to 1.15. Add 7 times the amount of water, refrigerate at 2°C to 8°C, let stand, and filter. Heat the filtrate at 120°C for 1 hour, refrigerate at 2°C to 8°C, let stand, add 0.2% activated carbon, and filter to obtain filtrate A.

[0030] (2) After washing the residue, add 0.03 times the amount of sodium bicarbonate and 4 times the amount of water for distillation, and collect the distillate;

[0031] (3) The distillate is mixed with the filtrate A, concentrated under reduced pressure to a clear paste with a relative density of 1.15 to 1.20, and dried under vacuum at 70°C to obtain the product.

[0032] Example 2 Preparation of Artemisia capillaris extract

[0033] (1) Remove impurities from the Artemisia capillaris, wash, chop, and dry in the sun. Take 50 g of the treated Artemisia capillaris, soak it in 85% ethanol as a solvent for 20 hours, and then perform percolation. Collect the percolation liquid, filter, and decompress the filtrate to a clear paste with a relative density of 1.10 to 1.15. Add 6 times the amount of water, refrigerate at 2°C to 8°C, let stand, and filter. Heat the filtrate at 100°C for 2 hours, refrigerate at 2°C to 8°C, let stand, add 0.1% activated carbon, and filter to obtain filtrate A.

[0034] (2) After washing the residue, add 0.01 times the amount of sodium bicarbonate and 3 times the amount of water for distillation, and collect the distillate;

[0035] (3) The distillate is mixed with the filtrate A, concentrated under reduced pressure to a clear paste with a relative density of 1.15 to 1.20, and dried under vacuum at 65°C to obtain the product.

[0036] Example 3 Preparation of Artemisia capillaris extract

[0037] (1) Remove impurities from the Artemisia capillaris, wash, chop, and dry in the sun. Take 50 g of the treated Artemisia capillaris, soak it in 90% ethanol as a solvent for 30 hours, and then perform percolation. Collect the percolation liquid, filter, and decompress the filtrate to a clear paste with a relative density of 1.10 to 1.15. Add 8 times the amount of water, refrigerate at 2°C to 8°C, let stand, and filter. Heat the filtrate at 100°C for 2 hours, refrigerate at 2°C to 8°C, let stand, add 0.5% activated carbon, and filter to obtain filtrate A.

[0038] (2) After washing the residue, add 0.05 times the amount of sodium bicarbonate and 5 times the amount of water for distillation, and collect the distillate;

[0039] (3) The distillate is mixed with the filtrate A, concentrated under reduced pressure to a clear paste with a relative density of 1.15 to 1.20, and dried under vacuum at 80°C to obtain the product.

[0040] Comparative Example 1 Preparation of Artemisia capillaris extract

[0041] (1) Remove impurities from the Artemisia capillaris, wash, chop, and dry in the sun. Take 50 g of the treated Artemisia capillaris, soak it in 90% ethanol as a solvent for 24 hours, and then perform percolation. Collect the percolation liquid, filter, and decompress the filtrate to a clear paste with a relative density of 1.10 to 1.15. Add 7 times the amount of water, refrigerate at 2°C to 8°C, let stand, and filter. Heat the filtrate at 120°C for 1 hour, refrigerate at 2°C to 8°C, let stand, add 0.2% activated carbon, and filter to obtain filtrate A.

[0042] (2) After washing the residue, add 4 times the amount of water for distillation and collect the distillate;

[0043] (3) The distillate is mixed with the filtrate A, concentrated under reduced pressure to a clear paste with a relative density of 1.15 to 1.20, and dried under vacuum at 70°C to obtain the product.

[0044] Comparative Example 2 Preparation of Artemisia capillaris extract

[0045] Remove impurities from the Artemisia capillaris, wash it, chop it, and dry it in the sun. Take 50g of the processed Artemisia capillaris, use 90% ethanol as a solvent, soak it for 24 hours, then perform percolation, collect the percolation liquid, filter it, and concentrate the filtrate under reduced pressure to a clear paste with a relative density of 1.10-1.15, add 7 times the amount of water, refrigerate it at 2℃-8℃, let it stand, filter it, heat the filtrate at 120℃ for 1h, refrigerate it at 2℃-8℃, let it stand, add 0.2% activated carbon, filter it, and concentrate the filtrate under reduced pressure to a clear paste with a relative density of 1.15-1.20, and dry it in a vacuum at 70℃.

[0046] Determination of active ingredients in Artemisia capillaris extract

[0047] The active ingredient chlorogenic acid is determined according to the HPLC method (General Rule 0512) of the 2020 edition of the Chinese Pharmacopoeia:

[0048] Chromatographic conditions and system suitability test: octadecylsilane bonded silica gel is used as filler; acetonitrile-0.05% phosphoric acid solution (10:90) is used as mobile phase; detection wavelength is 327nm. The number of theoretical plates calculated according to the chlorogenic acid peak should not be less than 10000. Preparation of reference solution: Take an appropriate amount of chlorogenic acid reference, accurately weigh it, place it in a brown volumetric bottle, add 50% methanol to make a solution containing 40μg per 1ml, and obtain it. Preparation of test solution: Take 0.3g of this product, accurately weigh it, place it in a 50ml brown volumetric bottle, add an appropriate amount of 50% methanol, ultrasonically dissolve it, cool it, add 50% methanol to the scale, shake it well, centrifuge it, accurately measure 3ml of the supernatant, place it in a 10ml brown volumetric bottle, add 50% methanol to the scale, shake it well, and obtain it. Determination method: Accurately aspirate 10-20μl of the reference solution and the test solution respectively, inject it into the liquid chromatograph, and determine it.

[0049] The active ingredient p-hydroxyacetophenone is determined according to the HPLC method (General Rule 0512) of the 2020 edition of the Chinese Pharmacopoeia:

[0050] Chromatographic conditions and system suitability test: octadecylsilane bonded silica gel is used as filler; acetonitrile-0.05% phosphoric acid solution (15:80) is used as mobile phase; detection wavelength is 275nm. The theoretical plate number calculated based on the p-hydroxyacetophenone peak should not be less than 10,000. Preparation of reference solution: Take an appropriate amount of p-hydroxyacetophenone reference substance, accurately weigh it, and add 50% methanol to make a solution containing 10μg per 1ml. Preparation of test solution: Take the supernatant after centrifugation under the [Content Determination] chlorogenic acid item, and obtain it. Determination method: Accurately aspirate 10-20μ1 of reference solution and test solution respectively, inject into liquid chromatograph, and determine, and obtain it.

[0051] The active ingredient volatile oil is measured by distillation weighing.

[0052] Table 1 Content of active ingredients in Artemisia capillaris extract

[0053] Chlorogenic acid (%) p-Hydroxyacetophenone (%) Volatile oil (g) Example 1 1.86 0.21 4.86 Example 2 1.73 0.19 4.01 Example 3 1.82 0.20 4.65 Comparative Example 1 1.44 0.15 2.05 Comparative Example 2 1.35 0.13 0

[0054] Table 1 shows that the content of effective ingredients in the Artemisia capillaris extract of the present invention is high.

[0055] Figure 1 The effect of sodium bicarbonate on the extraction efficiency of volatile oils shows that weak alkaline conditions can enhance the exudation of volatile oils, making it easier to distill them out with steam, thereby improving the extraction efficiency of Artemisia capillaris volatile oils.

[0056] 2. Tablets containing cetirizine and Artemisia capillaris extract

[0057] Example 4 Tablets containing cetirizine and Artemisia capillaris extract

[0058] formula:

[0059]

[0060] Preparation method:

[0061] Cetirizine hydrochloride is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule A; Artemisia capillaris extract is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule B; Granule A is mixed with granule B, a disintegrant and a lubricant are added, mixed evenly, and tableted to obtain the product.

[0062] Example 5 Tablets containing cetirizine and Artemisia capillaris extract

[0063] formula:

[0064]

[0065] Preparation method:

[0066] Cetirizine hydrochloride is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule A; Artemisia capillaris extract is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule B; Granule A is mixed with granule B, a disintegrant and a lubricant are added, mixed evenly, and tableted to obtain the product.

[0067] Example 6 Tablets containing cetirizine and Artemisia capillaris extract

[0068] formula:

[0069]

[0070]

[0071] Preparation method:

[0072] Cetirizine hydrochloride is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule A; Artemisia capillaris extract is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule B; Granule A is mixed with granule B, a disintegrant and a lubricant are added, mixed evenly, and tableted to obtain the product.

[0073] Comparative Example 3 Tablets containing cetirizine and Artemisia capillaris extract

[0074] formula:

[0075]

[0076] Preparation method:

[0077] Cetirizine hydrochloride is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule A; Artemisia capillaris extract is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule B; Granule A is mixed with granule B, a disintegrant and a lubricant are added, mixed evenly, and tableted to obtain the product.

[0078] Comparative Example 4 Tablets containing cetirizine and Artemisia capillaris extract

[0079] formula:

[0080]

[0081]

[0082] Preparation method:

[0083] Cetirizine hydrochloride is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule A; Artemisia capillaris extract is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granule B; Granule A is mixed with granule B, a disintegrant and a lubricant are added, mixed evenly, and tableted to obtain the product.

[0084] Comparative Example 5 Tablets containing cetirizine and Artemisia capillaris extract

[0085] formula:

[0086]

[0087] Preparation method:

[0088] Cetirizine hydrochloride is mixed with 1 / 2 portion of filler, granulated, sized to obtain granules, the remaining filler, disintegrant and lubricant are added, mixed evenly, and tableted to obtain the product.

[0089] Comparative Example 6 Tablets containing cetirizine and Artemisia capillaris extract

[0090] formula:

[0091]

[0092] Preparation method:

[0093] Cetirizine hydrochloride is mixed with 1 / 3 of the filler, granulated, and sized to obtain granules A. Artemisia capillaris powder (the Artemisia capillaris is washed and ground into fine powder and sieved) is mixed with 1 / 3 of the filler, granulated, and sized to obtain granules B. Granules A and B are mixed, and a disintegrant and a lubricant are added, and mixed evenly.

[0094] Press into tablets and you’re done.

[0095] 3. Pharmacodynamics Experiment

[0096] SD rats, SPF grade, 180-220g, experimental animal license number: SYXK (Lu) 20180008, were adaptively fed under standard conditions for 1 week before the experiment. Several rats were taken to establish an ovalbumin sensitization model. On the first day, 0.5 ml of sterile saline containing 10 μg OVA and 1 mg aluminum hydroxide gel was intraperitoneally injected for basic sensitization. On the 5th day, 0.5 ml of sterile saline containing 10 μg OVA was intraperitoneally injected for enhanced sensitization. Starting from the 6th day, 50 μl of 2 mg / ml OVA was dripped into the nose once a day for 14 consecutive days to stimulate the rats. The rats with successful modeling were divided into a model group, an embodiment 4 group, an embodiment 5 group, an embodiment 6 group, a comparative example 3 group, a comparative example 4 group, a comparative example 5 group, and a comparative example 6 group, with 10 rats in each group. The blank group was pseudo-sensitized and stimulated with sterile saline according to the same process, with 10 rats. The rats in each treatment group were given the corresponding drug (0.9 mg / kg in terms of cetirizine hydrochloride) by gavage, and the rats in the blank group and the model group were given an equal amount of normal saline by gavage, once a day, for 7 consecutive days.

[0097] Rat behavioral statistics

[0098] The number of sneezing and nasal wiping of rats in each group was counted on the 0th, 1st, 2nd, 3rd and 7th days of administration, and the obtained data were statistically analyzed using SPSS22.0 software. The quantitative data were expressed as (x±s). One-way analysis of variance was used for comparison among multiple groups, and independent sample T test was used for analysis between two groups. P<0.05 was considered statistically significant.

[0099] Typical symptoms of allergic rhinitis include paroxysmal sneezing, clear watery nasal discharge, nasal itching and nasal congestion. Figure 2 and Figure 3 The numbers of sneezing and wiping nose of rats in each group during the administration period are significantly different from those in each control group (P<0.01).

[0100] Serum IgE level

[0101] After anesthesia, blood was collected from the abdominal artery of each group of rats, and serum was separated. ELISA was performed according to the instructions of the kit to determine the IgE content in the rat serum.

[0102] IgE is an important marker for allergic reactions and its elevated levels are often associated with allergic diseases such as allergic rhinitis. Figure 4 The serum IgE content of rats in each group was expressed. The serum IgE content of rats in Example 4, Example 5 and Example 6 groups were significantly different from those in Comparative Example 3 to 6 groups (P<0.01).

[0103] EOS levels in nasal secretions

[0104] EOS levels in nasal secretions can be used as a biomarker for allergic rhinitis. In patients with allergic rhinitis, nasal secretions often show a significant increase in eosinophils. This is because allergic reactions trigger the activation of the immune system, causing eosinophils to migrate to the nasal mucosa. Figure 5 EOS is the nasal secretion level of each group of rats after administration. After administration, the nasal secretion of each group of rats showed a decreasing trend. The nasal secretion of rats in groups 4 to 6 of the embodiments of the present invention was significantly reduced, and the difference was significant compared with the rats in the other control groups, P < 0.01.

[0105] In summary, the combined use of cetirizine hydrochloride and Artemisia capillaris extract can enhance the therapeutic effect and improve the efficacy through different mechanisms. The above rat experiments confirmed that the tablets containing cetirizine and Artemisia capillaris extract in Examples 4 to 6 of the present invention can reduce the behaviors of allergic rhinitis in rats such as rubbing the nose and sneezing more quickly and more effectively than the comparative tablets, and can significantly reduce the serum IgE content and EOS level of nasal secretions in rats with allergic rhinitis, which is statistically significant.

[0106] 4. Granules containing cetirizine and Artemisia capillaris extract

[0107] Example 7 Granules containing cetirizine and Artemisia capillaris extract

[0108] formula:

[0109]

[0110] Preparation method:

[0111] Cetirizine hydrochloride is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule A; Artemisia capillaris extract is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule B; and the mixture is mixed to obtain the product.

[0112] Example 8 Tablets containing cetirizine and Artemisia capillaris extract

[0113] formula:

[0114]

[0115] Preparation method:

[0116] Cetirizine hydrochloride is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule A; Artemisia capillaris extract is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule B; and the mixture is mixed to obtain the product.

[0117] Example 9 Tablets containing cetirizine and Artemisia capillaris extract

[0118] formula:

[0119]

[0120] Preparation method:

[0121] Cetirizine hydrochloride is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule A; Artemisia capillaris extract is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule B; and the mixture is mixed to obtain the product.

[0122] 5. Capsules containing cetirizine and Artemisia capillaris extract

[0123] Example 10 Capsules containing cetirizine and Artemisia capillaris extract

[0124] formula:

[0125]

[0126]

[0127] Preparation method:

[0128] Cetirizine hydrochloride is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule A; Artemisia capillaris extract is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule B; the mixture is mixed and filled into capsules to obtain the product.

[0129] Example 11 Capsules containing cetirizine and Artemisia capillaris extract

[0130] formula:

[0131]

[0132] Preparation method:

[0133] Cetirizine hydrochloride is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule A; Artemisia capillaris extract is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule B; the mixture is mixed and filled into capsules to obtain the product.

[0134] Example 12 Capsules containing cetirizine and Artemisia capillaris extract

[0135] formula:

[0136]

[0137]

[0138] Preparation method:

[0139] Cetirizine hydrochloride is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule A; Artemisia capillaris extract is mixed with 1 / 2 part of filler, disintegrant and lubricant, granulated and sized to obtain granule B; the mixture is mixed and filled into capsules to obtain the product.

[0140] It should be noted that there is no significant difference in the effects of the granules containing cetirizine and Artemisia capillaris extract in Examples 7 to 9, the capsules containing cetirizine and Artemisia capillaris extract in Examples 10 to 12, and the tablets containing cetirizine and Artemisia capillaris extract in Examples 1 to 3 in the treatment of allergic rhinitis. These are only dosage form improvements made to adapt to the patient's compliance with medication.

Claims

1. A preparation containing cetirizine and Artemisia capillaris extract, characterized in that: The preparation consists of the following components: 5-15 parts by weight of cetirizine hydrochloride; 0.5-2.5 parts by weight of Artemisia capillaris extract; 5-20 parts by weight of disintegrant; 0.5-3 parts by weight of lubricant; Filler 160-360 parts by weight.

2. The preparation containing cetirizine and Artemisia capillaris extract according to claim 1, characterized in that: The disintegrant is selected from one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone.

3. The preparation containing cetirizine and Artemisia capillaris extract according to claim 1, characterized in that: The lubricant is selected from one or more of magnesium stearate, talcum powder, and micro-powdered silica gel.

4. The preparation containing cetirizine and Artemisia capillaris extract according to claim 1, characterized in that: The filler is selected from one or more of microcrystalline cellulose, lactose, mannitol, sucrose, starch, and dextrin.

5. The preparation containing cetirizine and Artemisia capillaris extract according to claim 1, characterized in that: The preparation method of the Artemisia capillaris extract is as follows: (1) Take Artemisia capillaris, soak it in 85% to 90% ethanol as a solvent for 20 to 30 hours, then perform percolation, collect the percolation liquid, filter, and decompress the filtrate to a clear paste with a relative density of 1.10 to 1.15, add 6 to 8 times the amount of water, refrigerate, let stand, filter, heat the filtrate at 100° C. to 120° C. for 1 to 2 hours, refrigerate, let stand, add 0.1% to 0.5% activated carbon, and filter to obtain filtrate A; (2) After washing the residue, add 0.01 to 0.05 times the amount of sodium bicarbonate and 3 to 5 times the amount of water for distillation, and collect the distillate; (3) The distillate is mixed with the filtrate A, concentrated under reduced pressure to a clear paste with a relative density of 1.15 to 1.20, and dried under vacuum at 65°C to 80°C to obtain the product.

6. The preparation containing cetirizine and Artemisia capillaris extract according to claim 5, characterized in that: The added amount of the sodium bicarbonate is 0.03 times.

7. The preparation containing cetirizine and Artemisia capillaris extract according to claim 5, characterized in that: The refrigeration temperature is 2°C to 8°C.

8. A method for preparing the preparation containing cetirizine and Artemisia capillaris extract according to claim 1, characterized in that: The method comprises the following steps: Cetirizine hydrochloride is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granules A; an Artemisia capillaris extract is mixed with 1 / 3 of a filler, granulated, and granulated to obtain granules B; granules A and B are mixed, a disintegrant and a lubricant are added, and the mixture is uniformly mixed to prepare a preparation.

9. The method according to claim 8, characterized in that The preparation is in the form of tablets, granules or capsules.

10. Use of the preparation containing cetirizine and Artemisia capillaris extract according to claim 1 in preparing a drug for treating rhinitis.

Images